Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment

Author: Juan Spínelli | August 14, 2024 02:13pm

Kaya Holdings, Inc. (OTCQB:KAYS), a company engaged in the emerging psilocybin treatment sector and medical/recreational cannabis, has voiced strong criticism of the FDA’s decision to reject MDMA therapy as a treatment for post-traumatic stress disorder (PTSD). KAYS, which operates The Sacred Mushroom, a psilocybin treatment facility in Portland, Oregon, advocates for psilocybin therapy as an alternative treatment for PTSD. It is extending an open invitation to those seeking this form of therapy under Oregon law.

CEO’s Response To FDA’s Decision

KAYS’ CEO, Craig Frank, expressed disappointment with the FDA’s decision. “We are deeply sorry the FDA has decided against MDMA use for the treatment of PTSD and regret the impact this may have on developing a PTSD treatment needed by so many, including numerous military veterans.” Frank added that psilocybin, legally authorized for use in Oregon, offers a promising alternative. He invited researchers and organizations to consider psilocybin therapy, positioning The Sacred Mushroom as “a safe, legal space where psilocybin may be administered in a comfortable, welcoming setting.”

Psilocybin: Viable Alternative To MDMA For PTSD Treatment

Recent studies have highlighted the potential of psilocybin to provide lasting therapeutic benefits after just one or two sessions. A study published in the Journal of Psychopharmacology reported that psilocybin-assisted therapy significantly reduced symptoms of depression and anxiety in patients with life-threatening cancer, conditions often accompanied by PTSD-like symptoms. Another study in Nature Medicine demonstrated that psilocybin-assisted therapy led to sustained improvements in PTSD symptoms among military veterans, particularly in reducing avoidance behaviors and hyper-arousal – key components of PTSD.

Comparing Psilocybin And MDMA In PTSD Therapy

Comparative research between MDMA and psilocybin, including studies at Kings College in London and Johns Hopkins University suggests several advantages of psilocybin therapy. Psilocybin experiences typically last longer than MDMA sessions, providing more time for psychological processing and integration of insights gained. While MDMA enhances empathy and connection without hallucinations, psilocybin induces a more introspective experience with visual and auditory hallucinations, potentially facilitating deeper psychological integration.

Furthermore, psilocybin generally presents milder physical side effects compared to MDMA, which can include changes in heart rate, dehydration, nausea, anxiety, agitation, sweating, and chills. Psilocybin also has a preferable safety profile concerning potential abuse and dependency risks.

As the conversation around alternative PTSD treatments continues, KAYS remains a strong advocate for the potential of psilocybin, positioning it as a viable and effective option, particularly in light of the FDA’s stance on MDMA.

Cover image made with AI

Posted In: KAYS